Get started

Verona Pharma plc

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

VRNA chart

Key stats

Market capitalization
1.081BUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.65USD
Net income
−68.659MUSD
Revenue
457.717KUSD
Shares float
60.876M
Beta
1.16

About Verona Pharma plc

Sector
Health Technology
CEO
David S. Zaccardelli
Headquarters
London
Website
veronapharma.com
Employees (FY)
36
Founded
2005
ISIN
US9250501064
Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Ideas

VRNA SELL +++++VRNA stock run up is way overdone. Leave it to scumbag analysts to upgrade a stock only after a major run up where are these douchebags when the stocks are cheap? Pump n dump much? Purchased a total of 70 puts so far will add for each $1 share price increase until correction
Short
by ShortSeller76
VRNA SELL++++ overboughtVRNA overbought on positive lung cancer results. These money losing pharma stocks always tend to overshoot. We should correct under $15 in coming days. Purchased 50 Feb 17th $20 puts. Will add for each $1 increase in share price.
Short
by ShortSeller76
4
VRNA Looking for a push above $12VRNA has some decent moves today during the first half of the day. The stock since the peak of the $14 zone has pulled back to the $9-$10 zone. Recently the stock was given an upgrade on Zacks for a strong buy which is always a good sentiment indicator from a business perspective. Could see another
by azheng2649
VRNA Three Falling Peaks (bearish)I found this pattern at tickeron website with the following data: STATUS = Confirmed CURRENT CONFIDENCE = 84% TARGET (EXIT) PRICE = 3.84 USD BREAKOUT (ENTRY) PRICE = 6.60 USD DISTANCE TO TARGET PRICE = 39.95% EMERGED ON = Aug 19, 12:00 PM (EDT) CONFIRMED ON = Sep 03, 01:03 PM (EDT) WITH CONFIDENCE L
Short
by AlTorress
1
200 Million in Oversubscribed Private Placement and SubscriptionVerona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription Funding to support Phase 3 ENHANCE clinical program in COPD The Financing comprises a private placement of 39,090,009 of the Company’s American Depositary Shares (“ADSs”), each representing eight ordinary shares
by AlenCiken

See all ideas 

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Earnings
‪0‬

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good
Learn more

See all brokers